In a filing, Rani Therapeutics Holdings Inc revealed its 10% Owner South Cone Investments Limited unloaded Company’s shares for reported $10.14 million on Oct 15 ’24. In the deal valued at $2.65 per share,3,829,360 shares were sold. As a result of this transaction, South Cone Investments Limited now holds 8,302,194 shares worth roughly $16.6 million.
Then, Imran Talat bought 10,000 shares, generating $22,700 in total proceeds. Upon buying the shares at $2.27, the Chief Executive Officer now owns 484,455 shares.
Before that, Imran Talat bought 5,000 shares. Rani Therapeutics Holdings Inc shares valued at $12,850 were divested by the Chief Executive Officer at a price of $2.57 per share. As a result of the transaction, Imran Talat now holds 474,455 shares, worth roughly $0.95 million.
Oppenheimer initiated its Rani Therapeutics Holdings Inc [RANI] rating to an Outperform in a research note published on August 02, 2024; the price target was $17. A number of analysts have revised their coverage, including Maxim Group’s analysts, who began to cover the stock in mid June with a ‘”a Buy”‘ rating. Rodman & Renshaw began covering RANI with “Buy” recommendation on June 13, 2024.
Price Performance Review of RANI
On Monday, Rani Therapeutics Holdings Inc [NASDAQ:RANI] saw its stock fall -0.99% to $2.00. Over the last five days, the stock has lost -3.85%. Rani Therapeutics Holdings Inc shares have fallen nearly -39.76% since the year began. Nevertheless, the stocks have risen 1.01% over the past one year. While a 52-week high of $8.75 was reached on 04/17/24, a 52-week low of $1.90 was recorded on 12/02/24. SMA at 50 days reached $2.30, while 200 days put it at $3.55.
Levels Of Support And Resistance For RANI Stock
The 24-hour chart illustrates a support level at 1.92, which if violated will result in even more drops to 1.84. On the upside, there is a resistance level at 2.06. A further resistance level may holdings at 2.12. The Relative Strength Index (RSI) on the 14-day chart is 39.47, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.14, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 87.22%. Stochastics %K at 10.20% indicates the stock is a buying.
How much short interest is there in Rani Therapeutics Holdings Inc?
A steep rise in short interest was recorded in Rani Therapeutics Holdings Inc stocks on 2024-10-31, growing by 0.7 million shares to a total of 1.49 million shares. Yahoo Finance data shows the prior-month short interest on 2024-09-30 was 0.79 million shares. There was a rise of 47.12%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on October 11, 2022 when UBS began covering the stock and recommended ‘”a Buy”‘ rating along with a $15 price target.
